Hengrui Medicine Independent Director Sun Jinyun Releases 2025 Performance Report, Focusing on Related Party Transactions and Executive Compensation

Log in to Sina Finance App and search for [Disclosure of Information] to see more evaluation levels.

China Inspection Network Data: Jiangsu Hengrui Medicine Co., Ltd. recently released the 2025 annual work report of independent director Sun Jinyun. The report shows that during his term in 2025, Sun Jinyun diligently performed his duties in accordance with relevant laws, regulations, and the company’s articles of association. He attended all 10 board meetings and 3 shareholder meetings, and expressed independent opinions on several important matters.

During his tenure, Sun Jinyun focused on related-party transactions, external guarantees, use of raised funds, and compensation of directors and senior management. Regarding the company’s expected routine related-party transactions in 2025, he believes the transactions are necessary for normal business operations, fairly priced, legally conducted, and do not harm the interests of the company or non-related shareholders. Upon verification, as of December 31, 2025, the company had no external guarantees or non-operational capital occupation by controlling shareholders. The use of raised funds was standard, with no violations found.

During the reporting period, Sun Jinyun actively participated in the work of the Audit Committee, Nomination Committee, and Remuneration and Assessment Committee of the Board of Directors. He participated in the review of periodic reports and internal audits by the Audit Committee, the election of vice chairman and appointment of general manager and senior vice president by the Nomination Committee, and the review of proposals such as the 2024 compensation implementation for directors and senior management and the 2025 employee stock ownership plan by the Remuneration and Assessment Committee. Additionally, he attended three special meetings of independent directors, reviewing related-party transactions including acquisitions of subsidiary equity and signing exclusive licensing agreements.

Sun Jinyun stated in the report that in 2025, he gained an in-depth understanding of the company’s operations through on-site visits to subsidiaries and communication with small and medium shareholders. He believes the company’s information disclosure is timely and accurate, internal controls are effective, the nomination and appointment procedures for directors and senior management are compliant, and the compensation plans are reasonable. Overall, the company provides full cooperation for the duties of independent directors, and he has fulfilled his responsibilities effectively, committed to safeguarding the overall interests of the company and the legitimate rights and interests of all shareholders, especially small and medium shareholders.

Massive information, precise analysis, all on Sina Finance App.